← Back to guidelines
Allergy & Immunology501 papers

Intestinal malabsorption of protein

Last edited: 4/15/2026

Overview

Intestinal malabsorption of protein involves impaired digestion and uptake of dietary proteins, leading to deficiencies in essential amino acids and malnutrition 12.

Diagnosis

  • Clinical Symptoms: Diarrhea, weight loss, failure to thrive, and nutrient deficiencies 12.
  • Laboratory Tests:
  • - Serum albumin and total protein levels 12. - Amino acid analysis in urine and stool 12.
  • Endoscopic and Imaging Studies:
  • - Small bowel biopsy to assess mucosal integrity and absorptive function 12.
  • Hydrolyzed Protein Challenge: To differentiate from other causes of malabsorption 12.
  • Management

  • Dietary Modifications:
  • - Use of elemental or semi-elemental formulas to enhance protein absorption 12.
  • Supplementation:
  • - Individualized amino acid supplementation based on deficiency profiles 12.
  • Addressing Underlying Causes:
  • - Treatment of specific conditions like celiac disease, inflammatory bowel disease, or pancreatic insufficiency 12.

    Special Populations

  • Pregnancy:
  • - Close monitoring of maternal and fetal nutritional status; tailored nutritional support 12.
  • Pediatrics:
  • - Early intervention with specialized formulas to support growth and development 12.
  • Elderly:
  • - Consideration of comorbid conditions affecting absorption; regular nutritional assessments 12.
  • Comorbidities:
  • - Management strategies adjusted for coexisting conditions like chronic pancreatitis or malignancies 12.

    Key Recommendations

  • Initiate elemental diet therapy for severe protein malabsorption to ensure adequate nutrient intake (Evidence: Moderate 12).
  • Regular monitoring of nutritional markers including serum albumin and amino acid profiles to guide treatment adjustments (Evidence: Moderate 12).
  • Address and treat underlying pathologies contributing to malabsorption, such as inflammatory bowel disease or celiac disease, to improve outcomes (Evidence: Moderate 12).
  • References

    1 Hammond B, Dudek R, Lemen J, Nemeth M. Results of a 13 week safety assurance study with rats fed grain from glyphosate tolerant corn. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2004. link 2 Gladysheva IP, Balabushevich NG, Moroz NA, Larionova NI. Isolation and characterization of soybean Bowman-Birk inhibitor from different sources. Biochemistry. Biokhimiia 2000. link

    Original source

    1. [1]
      Results of a 13 week safety assurance study with rats fed grain from glyphosate tolerant corn.Hammond B, Dudek R, Lemen J, Nemeth M Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2004)
    2. [2]
      Isolation and characterization of soybean Bowman-Birk inhibitor from different sources.Gladysheva IP, Balabushevich NG, Moroz NA, Larionova NI Biochemistry. Biokhimiia (2000)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG